27th Annual Meeting of the European Charcot Foundation, 21 - 23 November 2019, Baveno
Posters presented by Investigators:

Basic Studies
D'ISA Raffaele Italy
Electrophysiological and behavioural impairments in the cuprizone demyelination/remyelination mouse model - ID78
HOBART Jeremy United Kingdom 
A new patient-reported outcome (PRO) walking scale for Multiple Sclerosis clinical trials - ID88
United Kingdom 
Measuring Upper Limb Function (ULF) in MS Clinical Trials: Definition, Conceptualisation, Measurement - ID89
LARONI Alice  Italy 
Systematic mapping of global family-orientated educational offerings for people with multiple sclerosis and members of their support networks - ID74
NIKOLAIDIS Ioannis     Greece 
Humoral immunity following neural precursor cell administration in naive rodents - ID13
RIECKMANN Peter     Germany 
Long-Term Efficacy Including Clinical NEDA and Safety of Three-Times-Weekly Dosing Regimen Of Glatiramer Acetate: 7-Year Results of the Glatiramer Acetate Low-Frequency Administration (GALA) Open-Label Extension Study - ID33
TIENARI Pentti  Finland 
Somatic mutations in CD8+ cells in multiple sclerosis patients and controls - ID52

CENTONZE Diego Italy 
PEG-IFN BETA-1A PRE-FILLED PEN (PLEGRIDY®) improves satisfaction in patients with relapsing-remitting multiple sclerosis who were dissatisfied with other subcutaneous interferons (platinum study) - ID37
D'HAESELEER Miguel Belgium 
Feasibility of internet-based teleconsultation in patients with multiple sclerosis: a pilot study - ID75
COREY Ford United States  Twenty-Seven Years Of Continuous Treatment Of Multiple Sclerosis With Glatiramer Acetate: Long-Term Efficacy Results of the US Open-Label Extension Study - ID34
View poster - Abstract
HARRIS Sarah United States 
Use of epigenetic cell counting to determine the effect of ozanimod on circulating leukocyte subtypes in patients with relapsing multiple sclerosis - ID57
MONTALBAN Xavier Spain 
Effect of evobrutinib, a Bruton’s tyrosine kinase inhibitor, on immune cell and immunoglobulin levels over 48 weeks in a phase 2 study in relapsing multiple sclerosis - ID32
SEJBAEK Tobias Denmark 
Neurofilament light chain and levels of fatigue are reduced by dimethyl fumarate – fatigue is not related to neuroaxonal damage - ID97
STEINMAN Lawrence United States 
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study - ID56

ALOISI Francesca Italy  Cytotoxic CD8 T cells (the effectors) against EBV-infected B cells (the targets): clues for virus-driven immunopathology in multiple sclerosis - ID29
View posterAbstract
HUANG Su-Chun  Italy  Patterns of Neurodegeneration in Macula Differs in Multiple Sclerosis Subtypes: a Voxel-Based Morphometry Study with Optical Coherence Tomography - ID70
View poster - Abstract - Poster presentation recording
MESSINA Silvia  United Kngdom  Lesions distribution and normal appearing white matter in demyelinating diseases - ID86
View poster - Abstract
YOO Ronnie  United States  Updated incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time - ID84
View poster - Abstract

COOK Stuart United States 
Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Post-Approval Data - ID41
FREEDMAN Mark Canada 
Efficacy of subcutaneous interferon β-1a in patients with a first clinical demyelinating event: the REbif FLEXible dosing in early multiple sclerosis (REFLEX) study – outcomes in patients stratified by the 2017 McDonald criteria - ID39
GIOVANNONI Gavin United Kingdom 
Increase of naïve B cells M2 macrophages and reduction of memory B/T cells during immune repopulation at 96 weeks in CLARITY assessed by immune cell deconvolution - ID44
GIOVANNONI Gavin United Kingdom 
Long-term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies - ID45
HAUSER Stephen United States 
Exposure-Response Analyses of Ocrelizumab in Patients With Multiple Sclerosis - ID93
HULST Hanneke The Netherlands 
Cladribine decreases CD95 expressing CD4+ and CD8+ cells in lymphoid organs in naïve marmosets (Callithrix jacchus) - ID47
KAP Yolanda The Netherlands  No Correlation Between Lymphocyte Pharmacodynamics and Autoimmune Adverse Events Following Alemtuzumab Treatment in Patients With Relapsing-Remitting Multiple Sclerosis - ID43
View poster - Abstract
KUHLE Jens Switzerland  Effect of Interferon β-1a Treatment on Serum Neurofilament Light Chain Levels in Patients with a First Clinical Demyelinating Event in the REFLEX trial - ID40
View poster - Abstract
LEE Lily United States Characterizing the positive experience reported by natalizumab-treated patients with relapsing multiple sclerosis - ID55
View poster - Abstract - Poster presentation recording
RIECKMANN Peter Germany Expert Opinion on the Use of Cladribine Tablets in Clinical Practice for the Treatment of Relapsing Multiple Sclerosis - ID62
View poster - Abstract